FDA Grants Orphan Drug Designation to Cellenkos' CK0803 for ALS Treatment Innovations Cellenkos' CK0803 receives FDA Orphan Drug Designation for ALS, a crucial step towards potentially groundbreaking treatments for this rare disease.

FDA Grants Orphan Drug Designation to Cellenkos' CK0803 for ALS Treatment Innovations #United_States #Houston #ALS #Cellenkos #CK0803